Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23908005 | 0.72 | KDM4E (0.52) | LMNASMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL1188874 | 0.69 | KMT2A (0.36) | HTR2AHTR2CHTR2BLMNASMN1; SMN2 | |
| SCHEMBL23884128 | 0.68 | HTR2A (0.34) | HTR2AHTR2CHTR2BLMNASMN1; SMN2 | |
| SCHEMBL31218618 | 0.66 | HTR2A (0.42) | HTR2AHTR2CHTR2BLMNAKMT2A | |
| SCHEMBL629349 | 0.65 | JAK2 (0.35) | JAK2JAK1TYK2 | |
| SCHEMBL30832311 | 0.65 | HTR2A (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL25079178 | 0.64 | JAK2 (0.34) | JAK2JAK1TYK2 | |
| SCHEMBL31513103 | 0.63 | HTR2A (0.53) | HTR2AHTR2CHTR2BLMNASMN1; SMN2 | |
| SCHEMBL30832373 | 0.63 | HTR2A (0.40) | HTR2AHTR2CHTR2B | |
| SCHEMBL23884259 | 0.62 | L3MBTL1 (0.43) | LMNASMN1; SMN2KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932626-B2 | 2-pyrimidone analogs as potent antiviral agents against Alphaviruses | SOUTHERN RESEARCH INSTITUTE (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230120566-A1 | Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | OREGON HEALTH AND SCIENCE UNIVERSITY | 2023-04-20 | — | — | US | disclosed |
| CN-115916175-A | Novel 2-pyrimidinone analogs as potent antiviral agents against alphaviruses | 南方研究院 | 2023-04-04 | — | — | CN | disclosed |
| US-11566019-B2 | 2-pyrimidone analogs as potent antiviral agents against alphaviruses | SOUTHERN RESEARCH INSTITUTE (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220177452-A9 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-09 | — | — | US | disclosed |
| US-20210317106-A1 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | SOUTHERN RES INST (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317106-A1 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | EIF2AK2, ZC3HAV1, MAVS | HTR2A 3016/4885HTR2C 3189/4885HTR2B 4182/4885 |
| US-11566019-B2 | 2-pyrimidone analogs as potent antiviral agents against alphaviruses | EIF2AK2, ZC3HAV1, MAVS | HTR2A 3016/4885HTR2C 3189/4885HTR2B 4182/4885 |
| US-11932626-B2 | 2-pyrimidone analogs as potent antiviral agents against Alphaviruses | EIF2AK2, ZC3HAV1, MAVS | HTR2A 3016/4885HTR2C 3189/4885HTR2B 4182/4885 |
| US-20220177452-A9 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | EIF2AK2, ZC3HAV1, MAVS | HTR2A 3016/4885HTR2C 3189/4885HTR2B 4182/4885 |
| US-20230120566-A1 | Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | EIF2AK2, ZC3HAV1, MAVS | HTR2A 3274/4885HTR2C 3431/4885HTR2B 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.